PBS listing of Velsipity for treatment of UC

Pfizer Australia has announced the reimbursement of its oral S1P receptor modulator on the PBS for the treatment of moderate to severe active Ulcerative Colitis, as reported by Pharmacy Daily.

The PBS has listed Velsipity (etrasimod), which is indicated for adults with an inadequate response, loss of response or intolerance to conventional, biologic or JAK inhibitor therapies.

CCA CEO Leanne Raven welcomed the PBS listing.

“It’s encouraging to see treatments like Velsipity listed on the PBS, providing another subsidised treatment option for those who need it,” Raven said.